Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T

2008 Clin. Gastroenterol. Hepatol. Volume 6 Issue 7

PubMed 18524692 DOI 10.1016/j.cgh.2008.03.005

FibroTest SteatoTest Screening Metabolic Diseases Fibrosis Steatosis Diabetes


Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes.


We prospectively studied 1131 consecutive patients without a history of liver disease seen for diabetes. The biomarker data were obtained, and patients with presumed advanced fibrosis were reinvestigated by a hepatologist using elastography and, if necessary, ultrasonography, endoscopy, or liver biopsy.


The biomarker predicted advanced fibrosis in 63 of 1131 (5.6%) patients. A total of 45 patients was reinvestigated, and advanced fibrosis was confirmed in 32 patients, a 2.8% (32/1131) prevalence of confirmed advanced fibrosis, 5 cases of cirrhosis, and 4 cases of hepatocellular carcinoma. In the population with type 2 diabetes who were 45 years or older, the prevalence of confirmed advanced fibrosis was 4.3% (30/696), and hepatocellular carcinoma was 5.7 of 1000 (4/696).


The fibrosis biomarker might be used for the detection of advanced fibrosis in patients with type 2 diabetes.

Citation Reference: